• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc

    8/14/25 4:15:26 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRNA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Verona Pharma plc

    (Name of Issuer)


    Ordinary shares, nominal value 0.05 euro per share

    (Title of Class of Securities)


    925050106

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    925050106


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,507,591.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,507,591.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,507,591.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    925050106


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,507,591.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,507,591.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,507,591.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    925050106


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,507,591.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,507,591.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,507,591.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Verona Pharma plc
    (b)Address of issuer's principal executive offices:

    3 More London Riverside, London SE1 2RE, United Kingdom
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation
    (d)Title of class of securities:

    Ordinary shares, nominal value 0.05 euro per share
    (e)CUSIP No.:

    925050106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 689,536,966 outstanding Ordinary Shares, which if all held in ADS form, would be represented by 86,192,121 ADSs as of July 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025. Neither Perceptive Advisors nor Mr. Edelman directly holds any Ordinary Shares. The Master Fund directly holds 5,507,591 ADSs representing 44,060,728 Ordinary Shares Each ADS represents eight Ordinary Shares. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
    (b)Percent of class:

    Perceptive Advisors: 6.4% Mr. Edelman: 6.4% Master Fund: 6.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 5,507,591 Mr. Edelman: 5,507,591 Master Fund: 5,507,591

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 5,507,591 Mr. Edelman: 5,507,591 Master Fund: 5,507,591

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/14/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:08/14/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/14/2025
    Get the next $VRNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRNA

    DatePrice TargetRatingAnalyst
    7/14/2025Buy → Neutral
    H.C. Wainwright
    7/1/2025$170.00Outperform
    Wolfe Research
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    More analyst ratings

    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

    Acquisition aligns with Merck's science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Merck to hold investor call at 8 a.m. ET today Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 bill

    7/9/25 6:30:00 AM ET
    $MRK
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma Announces June 2025 Investor Conference Participation

    LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please

    5/21/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

    Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an

    5/6/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cunningham Kenneth converted options into 24,000 units of Ordinary Shares and sold $142,057 worth of Ordinary Shares (10,808 units at $13.14), increasing direct ownership by 20% to 79,776 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    8/5/25 8:32:17 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Deschamps Lisa converted options into 24,000 units of Ordinary Shares and sold $124,392 worth of Ordinary Shares (9,464 units at $13.14), increasing direct ownership by 21% to 84,856 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    8/5/25 8:31:14 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Fisher Andrew converted options into 20,888 units of Ordinary Shares and sold $125,969 worth of Ordinary Shares (9,584 units at $13.14), increasing direct ownership by 3% to 417,903 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    8/5/25 8:30:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    SEC Filings

    View All

    SEC Form DEFM14A filed by Verona Pharma plc

    DEFM14A - Verona Pharma plc (0001657312) (Filer)

    8/18/25 7:30:25 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc

    SCHEDULE 13G/A - Verona Pharma plc (0001657312) (Subject)

    8/14/25 6:14:37 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc

    SCHEDULE 13G/A - Verona Pharma plc (0001657312) (Subject)

    8/14/25 4:15:26 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Verona Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Verona Pharma from Buy to Neutral

    7/14/25 8:43:04 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Verona Pharma with a new price target

    Wolfe Research initiated coverage of Verona Pharma with a rating of Outperform and set a new price target of $170.00

    7/1/25 8:22:56 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Verona Pharma with a new price target

    TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

    4/28/25 8:38:21 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/18/24 4:20:05 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/7/24 6:57:21 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

    4 - Verona Pharma plc (0001657312) (Issuer)

    11/7/24 6:56:12 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

    ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

    4/29/21 2:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 5:46:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:50:28 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verona Pharma plc

    SC 13G - Verona Pharma plc (0001657312) (Subject)

    11/14/24 4:31:56 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VRNA
    Financials

    Live finance-specific insights

    View All

    Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

    4/29/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

    LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

    4/15/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

    2/27/25 6:00:00 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care